Knowledge Transfer Partnership Sponsored by the Department of Trade & Industry (DTI)

Posted:
4
July 2006

We are pleased to announce that we have launched a unique research project in conjunction with Queen Mary University of London.The Knowledge Transfer Partnership (KTP) sponsored by the Department of Trade and Industry (DTI), and Richmond Pharmacology Ltd is a two year project bringing together academia and commercial expertise.The project will culminate in the development of unique software tools, which will allow for the collection and linking of data from different medical measurement devices into one central repository for analysis.Dr Dilshat Djumanov PhD, a Research Associate from Queen Mary University of London, will undertake this two year research project.Dr Dilshat Djumanov Commented The Knowledge Transfer Partnership gives me the opportunity to undertake a demanding and exciting work based project, in which the results will be implemented in to a commercial environment. Working in conjunction with and having the support from Dr Peter Dabnichki Lecturer in Medical Engineering, Queen Mary University of London, and Dr Radivoj Arezina Research Director, Richmond Pharmacology, this 2 year project will offer Richmond Pharmacology expertise on data acquisition, data processing and software design to compliment and enhance the existing procedures.

Latest news

Upcoming Event

On Helix, Transforming new medicine discovery

13-14 July 2020
Richmond Pharmacology will be showcasing a presentation on Adaptive Early Phase Clinical Trials as part of the ON HELIX digital event.
View event

COVID-19 – External Monitoring Guidelines

July 1, 2020
Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.
Read more

First transdermal patch to treat schizophrenia hits market

March 18, 2020
The US Food and Drug Administration (FDA) has officially approved a transdermal patch to treat schizophrenia developed by Hisamitsu Pharmaceutical Co following successful
Read more

Statement: COVID-19

March 23, 2020
Richmond Pharmacology are continuously risk-assessing our activity in relation to the COVID-19 crisis and we are evaluating what activity can continue, what precautions need to be put in place and what needs to be suspended.
Read more